Transmuscular Quadratus Lumborum Block on Post-Operative Analgesia After Total Hip Arthroplasty

Not Applicable

• Conditions: Quadratus Lumborum Block
• Interventions: Procedure: Quadratus lumborum Block

• Registration Number: NCT05465967
• Lead Sponsor: Tanta University

Brief Summary

The aim of this study is to compare between the post-operative analgesic effect of two approaches of transmuscular quadratus lumborum block (transverse versus paraspinous sagittal transmuscular QLB) in total hip replacement surgery.

Detailed Description

During the preanesthetic assessment, all patients will be educated about the visual analogue scale (VAS) for pain assessment, with scores ranging from 0 to 10 (0 represent no pain, while10 represent maximum intolerable pain).

The patients will be randomly classified into three equal groups (25 patients each). Group allocation will be done by computer generated random numbers and closed opaque sealed envelopes. The study will be designed to be double blind as all patients and postoperative assessor will be blinded to group assignment.

Patients will be randomized to one of three equal groups:

* Group I: Control group (n= 25 patients): Patients in this group will receive ipsilateral sham ultrasound-guided block via subcutaneous injection of 1 ml of normal saline after surgery.

* Group II (n= 25 patients): Patients in this group will receive an ipsilateral single shot of transverse transmuscular approach of QLB (30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.

* Group III (n= 25 patients): patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of QLB (30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2021-09-01
• Status Verified: 2022-07
• Study First Submitted: 2022-07-07
• Study First Submitted QC: 2022-07-16
• Study First Posted: 2022-07-20
• Last Update Submitted: 2022-07-23
• Last Update Posted: 2022-07-26
• Primary Completion: 2022-08-01
• Study Completion: 2022-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• 75 patients, aged between 21- 80 years old, of both sex American society of Anesthesiology I - III scheduled for total hip replacement surgery.

Read More

Exclusion Criteria

• Patient refusal.
• Coagulopathy
• Spinal deformities
• Peripheral neuropathy; sensory disorders in the leg requiring surgery and chronic pain.
• Mental dysfunction, psychiatric illnesses and cognitive dysfunction.
• History of drug abuse &chronic analgesic use

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group I: Control Group	Quadratus lumborum Block	Patients in this group will receive ipsilateral sham ultrasound-guided block via subcutaneous injection of 1 ml of normal saline after surgery.
Group II:( transverse trans muscular Quadratus lumborum group).	Quadratus lumborum Block	patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK(30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.
Group III : paraspinous sagittal approach of Quadratus lumborum BLOCK	Quadratus lumborum Block	patients in this group will receive an ipsilateral single-shot of paraspinous sagittal approach of Quadratus lumborum BLOCK (30 ml of plain bupivacaine 0.25%) after surgery using ultrasonographic guidance.

Primary Outcome Measures

Name	Time	Method
Postoperative morphine consumption	Baseline	Total Morphine consumption in the first 24 h of the post-operative period .

Secondary Outcome Measures

Name	Time	Method
Postoperative pain score	Baseline	• Postoperative pain will be assessed by VAS (score for the severity of pain in the range 0-10, where 0 = no pain and 10 = severe pain) at 2,4,6,12,18,24 hours. If the VAS is 4 or more, 3 mg of intravenous morphine will be given as a rescue analgesia.

Trial Locations

Locations (1)

Tanata university hospital; 🇪🇬 Tanta, Egypt